Biochemistry

1909 Submissions

[23] viXra:1909.0196 [pdf] submitted on 2019-09-10 02:32:59

Influence of the Biofield Energy Treated Novel Test Formulation on Different Organ Specific Biomarkers

Authors: Lauree Ann Duprey-Reed, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 14 Pages.

The study aimed to evaluate the effect of the Biofield Energy Treated test formulation on the function of different vital organs viz. bones, heart, liver, lungs, and brain in multiple cell-based assays. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Lauree Ann Duprey-Reed, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI), BT-Med + UT-TI, and BT-Med + BT-TI groups showed 81.1% (at 1µg/mL), 78.4% (at 63µg/mL), and 87.9% (at 63µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med+ BT-TI group showed 80.4% and 89.9% restoration of cell viability at 0.1 and 1 µg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 181.3%, 93.2%, and 90.7% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1, 25, and 63 µg/mL, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 102.6%, 80.5%, and 100.5% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 40% (at 10µg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 156.2%, 80.1%, and 137.0% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1µg/mL compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.1% and 105.0% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 25 µg/mL compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 30.4% and 51.9% in the BT-Med + BT-TI group at 30 and 63 µg/mL, respectively compared to untreated in A549 cells. Serotonin level was significantly increased by 67.9% and 42.3% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1µg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 136.8%, 191.9%, and 165.8% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL compared to the untreated in MG-63 cells. Overall, the study outcomes suggest that the Biofield Energy Treated novel proprietary test formulation significantly improved the vital functional enzyme biomarkers relevant to bones, heart, liver, lungs, and brain. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.
Category: Biochemistry

[22] viXra:1909.0195 [pdf] submitted on 2019-09-10 02:34:23

Effect of the Biofield Energy Treated Test Formulation on Tissue Specific Biomarkers in Various Human Cells

Authors: Jagdish Singh, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 11 Pages.

Dysfunction of vital organs are the main concern for human health. Therefore, it is necessary to homeostat the normal function of vital organs such as lungs, liver, brain, and heart for better health. The aim of this study was to evaluate the effect of the Consciousness Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Jagdish Singh, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the tested formulation was safe and non-toxic in nature in six different cells. The experimental groups like untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI), BT-Med + UT-TI, and BT-Med + BT-TI showed 190.5%, 56.3%, and 73.8% restoration of cell viability at 1µg/mL in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, BT-Med + UT-TI and BT-Med + BT-TI groups showed 98.8% and 79.1% restoration of cell viability at 10µg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 261.7%, 165.8%, and 167.8% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1, 1, and 10µg/mL, respectively compared to untreated. Alkaline phosphatase (ALP) level was significantly increased by 52.5% and 66.1% in the BT-Med + UT-TI group at 10 and 50µg/mL, respectively in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by101% and 170.6%in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 50µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 191.8% (at 0.01µg/mL) and 141.8% (10µg/mL)in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 88.1% (at 1µg/mL) and 44.9% (at 63µg/mL) in the BT-Med + UT-TI and UT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 19.6% and 13.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 25µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 475.6% (at 0.1µg/mL), 311.9% (at 1µg/mL), 400.5% (at 10µg/mL) and 250.9% (at 63µg/mL) in the BT-Med + BT-TI group compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 185% and 285.8% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10µg/mL compared to the untreated in MG-63 cells. Utterly, these results suggest that Biofield Energy Treated test formulation significantly improved the relevant bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[21] viXra:1909.0194 [pdf] submitted on 2019-09-10 02:35:45

Impact of Biofield Energy Treatment Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Line Study

Authors: Ariadne Esmene Afaganis, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 15 Pages.

Multiple organ dysfunction syndrome or failure is one of the major concerns against healthcare services in order to maintain the normal function. The present study aimed to explore the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts, one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Ariadne Esmene Afaganis, Canada and was labeled as the Biofield Treated (BT) test formulation/media. The test formulation was tested for cell viability, and the data suggested that the test formulation was found safe and non-toxic against all the cell lines. Cytoprotective activity among the experimental groups showed a significant improved activity by 94.4% at 1 µg/mL in untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) group in human cardiac fibroblasts cells (HCF) cells, while 84.4% at 10 µg/mL in BT-Med + BT-TI groups in human hepatoma cells (HepG2), and 124% increased cytoprotective action at 1 µg/mL in UT-Med + BT-TI group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. ALP activity in MG-63 cells was significantly increased by 85.9% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 59.2% at 0.1 µg/mL in BT-Med + BT-TI groups as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 53% and 40.5% at 1 and 10 µg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 68.5%, 70.7%, and 16.8% at 0.1, 1, and 10 µg/mL respectively, and 86.5%, 62.5%, and 34.2% improved cellular protection at 0.1, 1, and 10 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 33.5%, 63.2%, and 99.2% at 10 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by increased by 39.8% (at 10 µg/mL), 44% (at 25.5 µg/mL), and 59.7% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated group. Serotonin level was significantly increased by 59.2% (at 0.1 µg/mL), 190.3% (at 0.1 µg/mL), and 201% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 159.1% (at 50 µg/mL), 212.7% (at 1 µg/mL), and 278.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the present data concluded that the overall multiple organ health using various standard biomarkers in specific cell lines were significantly improved with respect to health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). Thus, it can be used as a complementary and alternative therapy approach against many multiple organ disorders such as coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[20] viXra:1909.0193 [pdf] submitted on 2019-09-10 02:37:23

Impact of the Biofield Energy Healing Based Test Formulation on Various Health Biomarkers Using Cell-Based Assays

Authors: Elizabeth Patric, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 11 Pages.

Various complementary approaches have been used against multiple organ dysfunction syndrome (MODS), which is the major contributor in high mortality among the healthcare centers. The aim of the present study was to determine the impact of the Biofield Energy Treatment on test formulation and different cell line medium related with vital organs functioning. Different organ based cell lines were used in the study for testing the effects of test formulation. The test item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Elizabeth Patric, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 129.7% (at 1 µg/mL), 28.4% (at 63.75 µg/mL), and 44.5% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 53.4% (at 63.75 µg/mL), 14.5% (at 10 µg/mL), and 22.9% (at 25.5 µg/mL) improved cellular protection of human hepatoma cells (HepG2) cells in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 25.6% (at 25.5 µg/mL), 59.8% (at 10 µg/mL), and 26.1% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 84.9% at 50 µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 308.1% at 0.1 µg/mL in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 76.7% (at 1 µg/mL), 44.3% (at 1 µg/mL), and 102.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75 µg/mL by 70.6%, 89.9%, and 76.6% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 16.2% (at 10 µg/mL), 35.2% (at 63.75 µg/mL), and 17.7% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 14.6% (at 25 µg/mL), 41.2% (at 1 µg/mL), and 70.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 166.8%, 266.4%, and 153.3% at 0.1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[19] viXra:1909.0192 [pdf] submitted on 2019-09-10 02:38:12

Evaluation of the Impact of the Biofield Energy Treated Test Formulation on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells

Authors: Victoria Lee Vannes, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 9 Pages.

Vital organs dysfunctions are the major concern for human health worldwide. The study aim was to investigate the impact of Biofield Treated test formulation on vital organs function using cell-based assays. The test formulation/test item (TI) and cell media (Med) was divided into two parts; one untreated (UT) and other part received the Biofield Treatment remotely by a renowned Biofield Energy Healer, Victoria Lee Vannes, USA and was labeled as Biofield Treated (BT) test formulation/media. Based on the cell viability test formulation was found safe in six different cells. The test formulation groups showed 112.6% and 108.65% restoration of cell viability in human cardiac fibroblasts cells (HCF); while, 845.63% restoration of cell viability in human hepatoma cells (HepG2) compared to UT-Med + UT-TI group. Furthermore, 131.86% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) than untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.87%, 99.06%, and 105.13% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) than untreated. Additionally, ALP level was significantly increased by 150.97%, 382.08%, and 471.4% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 0.1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) than untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 115.1% (1 µg/mL) and 165.77% (10 µg/mL)in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 117.65% (1 µg/mL) and 91.3% (63 µg/mL) in UT-Med + BT-TI and BT-Med + BT-TI, respectively than untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 40.56% in UT-Med + BT-TI at 10 µg/mL than untreated. Serotonin level was significantly increased by 543.84% (1 µg/mL), 477.12% (10 µg/mL), and 457.22% (10 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively than untreated. The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 186.96%, 341.43%, and 291.31% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 1 µg/mL than untreated. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Therefore, the Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[18] viXra:1909.0169 [pdf] submitted on 2019-09-09 01:54:11

Cell-Based Vital Organs Specific Biomarkers Assessment using Biofield Energy Based Novel Test Formulation

Authors: Janice Patricia Kinney, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 15 Pages.

The aim of the present study was to determine the impact of Biofield Energy Treated test formulation using six different cell-lines. The test formulation/item (TI) and cell media (Med) was divided into two parts; one part was untreated (UT) and other part received Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Janice Patricia Kinney, USA and labeled as Biofield Energy Treated (BT) test item (TI)/ media. Based on cell viability assay, test formulation was found as safe at tested concentrations. Cytoprotective activity of test formulation showed a significant restoration of cell viability by 60.6% (10 µg/mL), 67.5% (63.75 µg/mL), and 117.5% (63.75 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI, respectively compared to untreated in human cardiac fibroblasts cells (HCF) cells. Moreover, restoration of cell viability was improved by 64% and 127.3% in UT-Med + BT-TI and BT-Med + UT-TI, respectively at 1 µg/mL compared to untreated in human liver cancer (HepG2) cells. Cellular restoration in A549 cells was improved by 314% and 112.3% at 1 µg/mL in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated. ALP activity in Ishikawa cells was significantly increased by 175.5%, 547.2%, and 220.8% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 0.1 µg/mL as compared to untreated. Additionally, in MG-63 cells showed increased ALP activity by 76.9%, 78.4%, and 79% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 50 µg/mL compared to untreated. The percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 60.6% (10 µg/mL), 67.5% (63.75 µg/mL), and 117.5% (63.75 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively as compared to untreated. An improved HepG2 cells protection (represents decreased ALT activity) by 115.1% (1 µg/mL), 42.5% (25.5 µg/mL), and 60.8% (10 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI, respectively as compared to untreated. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was significantly increased by 191.1% and 81.4% at 0.1 µg/mL in UT-Med + BT-TI and BT-Med + BT-TI, respectively as compared to untreated. Serotonin level was significantly increased by 31.8% (10 µg/mL) and 56.9% (25.5 µg/mL) in UT-Med + BT-TI and BT-Med + BT-TI, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). Relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 304.3% (0.01 µg/mL), 128.4% (0.1 µg/mL), and 240% (0.1 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively compared to untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) significantly improved organ specific functional biomarkers and would be useful for multiple organs health related to coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[17] viXra:1909.0168 [pdf] submitted on 2019-09-09 01:54:42

Role of the Biofield Energy Treated Test Formulation on Different Vital Organ Specific Biomarkers

Authors: William Dean Plikerd, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 10 Pages.

The present study was undertaken to evaluate the impact of the Biofield Energy Treated test formulation using cell lines relat-ed with vital organs functioning. In vitro cells based assay were performed to study the effects on the bones, heart, liver, lungs, and brain cells. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, William Dean Plikerd, USA and labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found safe and non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 133.4% (at 1 µg/mL), 65.7% (at 10 µg/mL), and 86.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while improved restoration of cell viability by 97.4% (at 1 µg/mL), 85.7% (at 10 µg/mL), and 81.9% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respect-tively, as compared to the untreated test group in HepG2 cells. Cellular restoration in A549 cells was improved by 174.2%, 472.6%, 118%, and 279.2% at 0.1, 1, 10, and 25.5 µg/mL respectively, in the BT-Med + UT-TI group, while 1514%, 1654.8%, 449.8%, and 540.4% improved cellular restoration was reported at 0.1, 1, 10, and 25.5 µg/mL respectively, at BT-Med + BT-TI groups as compared to the untreated test group. ALP activity in MG-63 cells was significantly increased by 93.4% at 50 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 107.4% at 50 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 35.9% at 10 µg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 69.3% at 1 µg/mL, and improved cellular protection by 119.1% and 44% at 1 and 10 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) activity was reported in terms of percent cellular protection of HepG2 (liver) cells. Results showed improved HepG2 cells protection (represents decreased ALT activity) by 23.8% (at 10 µg/mL), 98.1% (at 25.5 µg/mL), and 97.6% (at 25 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was increased by 73.5%, 109.8%, and 97.7% at 0.1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respect-tively as compared to untreated group. Serotonin level was significantly increased 68% (at 25 µg/mL), 75.7% (at 0.1 µg/mL), and 57.2% (at 25 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 16.4% (at 10 µg/mL), 182% (at 50 µg/mL), and 137.1% (at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organs health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[16] viXra:1909.0167 [pdf] submitted on 2019-09-09 01:55:20

Biofield Energy Treatment Based Test Formulation as a Novel and Efficient Approach on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells

Authors: Laura Nelson Streicher, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 15 Pages.

Multiple organ dysfunction syndromes (MODS) are one of the common reasons for increased mortality rate against healthcare services. The present experiment aimed to determine the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Laura Nelson Streicher, and USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay. The test formulation was tested for cell viability, and the results showed that the test formulation was found non-toxic against all the cell lines at the tested concentrations. Cytoprotective activity among the experimental groups showed a significant improved activity by 156.9% at 1 µg/mL in UT- medium (Med) + BT - test item/formulation (TI) group in human cardiac fibroblasts cells (HCF) cells, while 94.5% at 25.5 µg/mL in the UT-Med + BT-TI group in human hepatoma cells (HepG2), and 92.4% at 63.75 µg/mL in the BT-Med + BT-TI group as compared with the untreated test group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. Alkaline phosphatase (ALP) activity in MG-63 cells was significantly increased by 80.2% and 93.5% at 10 and 50 µg/mL respectively in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 51.5% at 1 µg/mL in UT-Med + BT-TI group as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of lactate dehydrogenase-LDH activity) was significantly increased by 156.9% and 18.3% at 1 and 10 µg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 24.5% and 17.7% at10 and 25.5 µg/mL respectively, and 67.1%, 32.2%, 47.7%, and 73.1% improved cellular protection 1, 10, 25.5, and 63.75 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 93.1% and 64.1% at 1 µg/mL in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively as compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of superoxide dismutase-SOD activity) in terms of percentage was increased by 20.6% (at 0.1 µg/mL) and 6.9% (at 10 µg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 59.3% (at 10 µg/mL), 55.6% (at 1 µg/mL), and 100.1% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 150.6% (at 50 µg/mL), 380.1% (at 10 µg/mL), and 148.1% (at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, test formulation would be significantly useful for multiple organ health and improve overall health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). As a complementary and alternative therapy, Biofield Energy approach can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[15] viXra:1909.0126 [pdf] submitted on 2019-09-07 01:25:42

Biofield Energy Therapy: Role in Multiple Organ Health Specific Biomarkers in Cell-Based Assay

Authors: Sakina Aleemah Ansari, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 15 Pages.

The major cause of high rate of mortality is the multiple organ dysfunction among critical care healthcare services. The aim of the current study was to evaluate the impact of the Biofield Energy Treated test formulation using standard and specific cell lines related with vital organs functioning. The test formulation and the specific cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Sakina Aleemah Ansari, USA and labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found safe and non-toxic. Cytoprotective activity showed improved cellular restoration by 105.4% (at 25 µg/mL), 32.8% (at 25 µg/mL), and 151.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in the human cardiac fibroblasts cells (HCF) cells, while improved restoration of cell viability by 22.4% (at 25.5 µg/mL), 67.1% (at 10 µg/mL), and 72.9% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in HepG2 cells. Cellular restoration in A549 cells was improved by 9.3%, 70.4%, and 14.1% at 0.1, 1, and 25.5 µg/mL respectively, in the BT-Med + UT-TI group, while 3% and 4.6% improved cellular restoration was reported at 10 and 25.5 µg/mL respectively, at BT-Med + BT-TI groups as compared to the untreated test group. ALP activity in Ishikawa cells was significantly increased by 68.4%, 41.1%, and 18.8% at 0.1, 10, and 50 µg/mL respectively, in the UT-Med + BT-TI group, while in MG-63 cells showed maximum increased ALP activity by 92.7%, 84.5%, and 93.2% respectively in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI group respectively, at 50 µg/mL as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 51.6%, 88.7%, and 53.7% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 10 µg/mL as compared to the untreated group. Alanine amino transferase (ALT) activity was reported in terms of percent cellular protection of HepG2 (liver) cells. The test data showed improved HepG2 cells protection (represents decreased ALT activity) by 33%, 90.2%, and 72.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, at 25 µg/mL as compared to the untreated test group. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was increased by 21.5% at 25.5 µg/mL in the UT-Med + BT-TI, while 33.4%, 25.8%, and 21.5% at 1, 10, and 25.5 µg/mL respectively, in the BT-Med + UT-TI group, and 12.8% increased SOD activity at 25.5 µg/mL in the BT-Med + BT-TI groups as compared to the untreated group. Serotonin level was significantly increased 137.4% (at 0.1 µg/mL), 65.4% (at 0.1 µg/mL), and 77.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 24.2% (at 1 µg/mL), 213.7% (at 10 µg/mL), and 328.7% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the data concluded that The Trivedi Effect® would be significantly useful for improving multiple organs health, which can be used for many coronary artery diseases, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[14] viXra:1909.0125 [pdf] submitted on 2019-09-07 01:26:17

In Vitro Cell-Based Biomarkers Study of Vital Organs: Impact of the Biofield Energy Based Test Formulation

Authors: Krista Joanne Callas, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 16 Pages.

The present study was undertaken to evaluate the impact of Biofield Energy Treated test formulation using multiple cell-lines. The test formulation and cell media (Med) was divided into two parts; one part was untreated (UT) and other part received Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Krista Joanne Callas, USA and labeled as Biofield Energy Treated (BT) test item (TI)/Med. Based on cell viability, test formulation was found safe. Cytoprotective action of test formulation showed significant restoration of cell viability by 89.9% and 106.4% in human cardiac fibroblasts cells (HCF) cells, while improved restoration of cell viability by 77.3% and 69% in HepG2 cells compared to untreated. Cellular restoration in A549 cells was also improved by 141.2% and 157.1% compared to untreated. ALP activity was significantly increased by 118.7% and 140.7% in UT-Med + BT-TI and BT-Med + UT-TI, respectively at 0.1 µg/mL than untreated. Percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 89.9% and 106.4% in UT -Med + BT-TI and BT-Med + BT-TI, respectively than untreated. HepG2 cells protection (decreased ALT activity) was increased by 59.8% in BT-Med + BT-TI than untreated. Superoxide dismutase (SOD) level was increased by 22.8% in BT-Med + BT-TI than untreated. Serotonin level was significantly increased by 361.7% and 197.6% in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated in human neuroblastoma cells (SH-SY5Y). However, relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 116.5%, 214.7%, and 241.5% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively than untreated in MG-63 cells. Overall, data showed a significant improvement of organ-specific functional enzyme biomarkers. Thus, Biofield Energy Treated Test formulation (the Trivedi Effect®) would be useful for multiple organs health that can be beneficial against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[13] viXra:1909.0124 [pdf] submitted on 2019-09-07 01:26:54

The Potential Health Benefits of the Consciousness Energy Treated Novel Test Formulation on Various Functional Enzyme Biomarkers

Authors: Shirley Theresa Holmlund, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 13 Pages.

The study objective was to investigate the effect of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Shirley Theresa Holmlund, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in six different cells. The Biofield Energy Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 115.6% and 53.3% restoration of viable cells at 10 and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + UT-TI group showed 113.5% and 73.5% restoration of cell viability at 0.1 and 1 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 101.1%, 829.8% and 698.9% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 97.9% and 69.7% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 58.2% in the BT-Med + BT-TI group at 1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 67.4% (at 0.1 µg/mL), 80.4% (at 0.1 µg/mL) and 119.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively compared to the untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.6% and 82.5% in the BT-Med + UT-TI group at 25 and 63 µg/mL, respectively; while 123.9% at 10 µg/mL in the BT-Med + BT-TI group compared to untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 53.6% and 59% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to the untreated. Serotonin level was significantly increased by 85.3% in the UT-Med + BT-TI and BT-Med + BT-TI groups at 0.1 µg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 245.9% and 211.5% at 10 and 50 µg/mL, respectively in the UT-Med + BT-TI group; while 174.3% (at 10 µg/mL) in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs and brain functional enzymes biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, hemochromatosis, cirrhosis, liver cancer, pneumonia, emphysema, chronic bronchitis, asthma, osteoporosis, cystic fibrosis, etc.
Category: Biochemistry

[12] viXra:1909.0117 [pdf] submitted on 2019-09-07 06:14:59

Evaluation of the Biofield Energy Treated Novel Test Formulation on Overall Organs Health Specific Biomarkers

Authors: John Suzuki, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 14 Pages.

The aim was to study the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media were divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, John Suzuki, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Treated medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 91.6%, 56.9%, and 114.5% restoration of cell viability at 1, 10, and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, BT-Med + BT-TI group showed 70.6%, 126.3%, and 60.2% restoration of cell viability at 1, 25, and 63 µg/mL, respectively; while 78.5% in the UT-Med + BT-TI group in human hepatoma cells (HepG2) compared to untreated. Furthermore, 72.6% (at 0.1 µg/mL), 57.4% (at 25 µg/mL), and 90.4% (at 63 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + UT-TI, UT-Med + BT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 82.2% and 106.6% in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively at 10 µg/mL; while 80.2% (at 10 µg/mL) in the BT-Med + BT-TI group in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 90.2% (at 0.1 µg/mL) and 78.3% (at 10µg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 63.7%, 59.6%, and 63.3% at 1, 10, and 25 µg/mL, respectively in the BT-Med + BT-TI group; while 122.2% (at 0.1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 62.8% and 153.2% at 1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 133.1%, 153.8%, and 107.5% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to untreated. Serotonin level was significantly increased by 75.7% (at 10 µg/mL), 124.1% (at 10 µg/mL), and 73.5% (at 10 µg/mL) in the BT-Med + UT-TI group at 10, 25, and 63 µg/mL, respectively; while 107.7% (at 25 µg/mL) in the BT-Med + BT-TI group as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 162.2% (at 10 µg/mL), 193.3% (at 1 µg/mL), and 148.7% (at 0.01 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, Wilson disease, liver cancer, hemochromatosis, pneumonia, asthma, cystic fibrosis, emphysema, chronic bronchitis, osteoporosis, etc.
Category: Biochemistry

[11] viXra:1909.0116 [pdf] submitted on 2019-09-07 06:15:46

Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs Function using Cell-Based Assays

Authors: Thomas Charles Slade, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 13 Pages.

Dysfunction of vital organs is the main concern for human health. Therefore, it is necessary to homeostat the normal function of vital organs such as lungs, liver, brain and heart for better health. The aim of this study was to evaluate the effect of the Consciousness Energy Healing Treated test formulation on the function of vital organs in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Thomas Charles Slade, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the tested formulation was safe and non-toxic in nature in six different cells. The experimental groups like the untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) and BT-Med + BT-TI groups showed 74.4% (at 10 µg/mL) and 73.7% (at 1 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI and BT-Med + BT-TI groups showed 76.4% (at 10 µg/mL) and 87.5% (at 1 µg/mL) restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 209.5%, 757.8% and 836.2% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively, at 1 µg/mL compared to the untreated. Alkaline phosphatase (ALP) level was significantly increased by 71.7%, 71.9% and 56.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human bone osteosarcoma cells (MG-63) at 50 µg/mL compared to the untreated. Additionally, the level of ALP was also significantly increased by 124.9% and 106.3% in the BT-Med + BT-TI group at 25 and 50 µg/mL, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 88.3% and 75.5% in the BT-Med + BT-TI group at 1 and 10 µg/mL, respectively; while 82.8% (at 0.1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 47.5%, 79.8% and 94% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to the untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 67.4%, 60.8% and 80.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL; while 137% (at 0.1 µg/mL) in the BT-Med + BT-TI group as compared to the untreated group. Serotonin level was significantly increased by 225.7% (at 1 µg/mL), 176.1% (at 25 µg/mL) and 175.7% (at 63 µg/mL) in the BT-Med + BT-TI group; while 317.9% (at 1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 195.3% (at 1 µg/mL), 176.2% (at 10 µg/mL) and 194.7% (at 50 µg/mL) in the BT-Med + BT-TI group compared to the untreated group in MG-63 cells. Altogether data suggest that these results suggest that Biofield Energy Treated test formulation significantly protect the major organs viz. bones, heart, liver, lungs and brain and also improved their functions. Therefore, The Biofield Energy Treatment (The Trivedi Effect®) can be used as a complementary and alternative therapy against several disorders such as heart attack, heart failure, coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, asthma, pneumonia, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.
Category: Biochemistry

[10] viXra:1909.0115 [pdf] submitted on 2019-09-07 06:16:47

Comprehensive Vital Organ Biomarkers Analysis of the Consciousness Energy Healing Based Novel Test Formulation Using Various Cell-lines

Authors: Alan Joseph Balmer, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 13 Pages.

The aim was to study the effect of the Consciousness Energy Treated test formulation on vital organ functions viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media were divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Alan Joseph Balmer, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was found as safe and non-toxic in six different cells. The Biofield Energy Treated medium (BT-Med) + Biofield Energy Treated Test Item (BT-TI) group showed 181% and 82.2% restoration of cell viability at 1 and 10 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. The UT-Med + BT-TI group showed 126.8% and 86.3% restoration of cell viability at 10 and 25 µg/mL, respectively with respect to the untreated group in human hepatoma cells (HepG2). Furthermore, 101.2% (at 10 µg/mL), 103.6% (at 10 µg/mL) and 135% (at 25 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 90%, 87.3% and 86.9% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 137% in the BT-Med + UT-TI group in human endometrial adenocarcinoma cells (Ishikawa) at 1 µg/mL compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 52.1%, 65.9% and 63.5% at 1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 157% and 58.9% at 0.1 and 10 µg/mL, respectively in the BT-Med + BT-TI group compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 168% and 135.4% in the UT-Med + BT-TI group at 10 and 25 µg/mL, respectively; while, 137% at 10 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. Serotonin level was significantly increased by 50.8% (at 63 µg/mL), 78.8% (at 63 µg/mL) and 52.7% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 265.5% (at 0.1 µg/mL) and 253.4% (at 1 µg/mL) in the UT-Med + BT-TI group; while 335.3% (at 0.1 µg/mL) in the BT-Med + BT-TI group compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver, lungs and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, Wilson disease, liver cancer, hemochromatosis, pneumonia, asthma, cystic fibrosis, emphysema, chronic bronchitis, osteoporosis, etc.
Category: Biochemistry

[9] viXra:1909.0092 [pdf] submitted on 2019-09-03 06:52:00

Assessment of the Biofield Energy Healing Based Test Formulation on Human Organ Health Specific Biomarkers In Vitro Assays

Authors: Eileen Mary Meagher, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 11 Pages.

Herbal based test formulations have been used in most of the healthcare settings since time immemorial. The present experimental cell line study was designed to evaluate the impact of the Biofield Energy Treatment on test formulation and different cell line mediums related with vital organs functioning. Cell lines that were specific to different organ systems were used in the study using standard protocols. The Test Item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Eileen Mary Meagher, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 56.8% (at 63.75µg/mL), 57.5% (at 63.75µg/mL), and 124.8% (at 1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group in Human Cardiac Fibroblasts cells (HCF) cells, while 83.2% (at 63.75µg/mL), 93.8% (at 63.75µg/mL), and 20.6% (at 10µg/mL) improved cellular protection of human Hepatoma cells (HepG2) cells in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 11.3% (at 25.5µg/mL), 82.7% (at 63.75µg/mL), and 113.9% (at 25.5µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. MG-63 cells were used for estimation of ALP activity, which was highly increased by 59.8% (at 0.1µg/mL), 269.7% (at 0.1µg/mL), and 105.7% (at 0.1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Besides, Ishikawa cells showed maximum increased ALP activity by 94.8% at 10µg/mL in the BT-Med+UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 48.8% (at 1µg/mL), 62.9% (at 10µg/mL), and 103% (at 1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI group, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Alanine Amino Transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75µg/mL by 74.9% and 84.9% in the BT-Med+UT-TI and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 21.7% (at 25.5µg/mL), 83.2% (at 0.1µg/mL), and 40% (at 25.5µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 50.8% (at 63.75µg/mL), 35.9% (at 10µg/mL), and 49.9% (at 10µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the Relative Quantification (RQ) of Vitamin D Receptor (VDR) was significantly increased by 135.2%, 291.4%, and 248.3% at 50µg/mL in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[8] viXra:1909.0077 [pdf] submitted on 2019-09-05 05:28:06

Investigation of Vital Organ Specific Biomarkers Using Cell-Based Assays after Treatment with the Biofield Energy Treated Test Formulation

Authors: James Jeffery Peoples, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 15 Pages.

The present study aimed to determine the impact of the Biofield Energy Treated test formulation and different cell line mediums on vital organs function. Specific cell based assays were performed based on the vital organs function (bones, heart, liver, lungs, and brain). The test item (TI) and cell line media was divided into two parts; one was untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, James Jeffrey Peoples, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found non-toxic against all the cell lines. Cytoprotective action of the test formulation showed a significant restoration of cell viability by 48.3% (at 25.5 µg/mL), 9.3% (at 1 µg/mL), and 64.1% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 48.3% (at 25.5 µg/mL), 9.3% (at 1 µg/mL), and 64.1% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. However, cytoprotective activity in human hepatoma cells (HepG2) showed improved cell viability by 65.4% (at 1 µg/mL), 63.8% (at 1 µg/mL), and 39.4% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinomic human alveolar basal epithelial cells (A549) showed improved cell viability by 28.4% (at 10 µg/mL), 101.7% (at 25.5 µg/mL), and 181.7% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 88.1% at 50 µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 433.3% and 136.1% at 0.1 and 10 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 87.8% at 1 µg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 40.1% at 10 µg/mL, and improved cellular protection by 70.1% at 1 µg/mL in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 35.6% (at 10 µg/mL), 19% (at 10 µg/mL), and 61.2% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 102.3% (at 1 µg/mL), 10.3% (at 25.5 µg/mL), and 38.4% (at 10 µg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 23.7% (at 0.1 µg/mL), 36.8% (at 25 µg/mL), and 51.9% (at 25 µg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 471% (at 10 µg/mL), 318.9% (at 10 µg/mL), and 326.2% (at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[7] viXra:1909.0076 [pdf] submitted on 2019-09-05 05:28:41

Impact of the Consciousness Energy Healing-based Novel Test Formulation on Human Organ Specific Biomarkers

Authors: Vicki Lynn Kindy, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 9 Pages.

The study was investigated to find out the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation/test item (TI) and the cell media (Med) was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Vicki Lynn Kindy, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI), BT-Med + UT-TI, and BT-Med + BT-TI groups showed 116.4% (at 1 µg/mL), 84.1% (at 63 µg/mL), and 98.5% (at 63 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, UT-Med + BT-TI group showed 62.5%, 156.8%, and 82.4% restoration of cell viability at 0.1, 1, and 10 µg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 224.2% and 295.6% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI group at 1 and 10 µg/mL, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 85.3%, 72.2%, and 79.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by161% (at 0.1 µg/mL), 84.5% (at 25 µg/mL), and 63.9%(at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 189.7% (at 0.01 µg/mL) and 51.7% (at10 µg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 95.1% (at 25 µg/mL), 63.2% (at 1 µg/mL), and 112% (at 63 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 36.9% and 44.1% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1 µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 199.5%, 168.7%, and 83.9% in the BT-Med + BT-TI group at 0.1, 1, and 10 µg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 205.2% (at 10 µg/mL), 189% (at 0.01µg/mL), and 315.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.
Category: Biochemistry

[6] viXra:1909.0075 [pdf] submitted on 2019-09-05 05:29:43

The Role of the Consciousness Energy Healing Treated Novel Test Formulation on Different Vital Organ Functional Biomarkers

Authors: Su-Mei Chen Liu, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 16 Pages.

The study objective was to investigate the potential of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs, and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Su-Mei Chen Liu, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental groups of Biofield Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 53.5% (at 0.1 µg/mL), 127.9% (at 10 µg/mL), and 53.3% (at 25 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI group showed 144% and 87.9% restoration of cell viability at 1 and 10 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 195%, 242.5%, and 117.5% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 0.1 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.2% (at 10 µg/mL) in the BT-Med + BT-TI; while 87.6%, 90.5%, and 90.3% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 249.5% and 167.4% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 94.5% (at 0.1 µg/mL) and 77.7% (at 25 µg/mL) in the BT-Med + BT-TI groups, respectively; while 58.4% (at 10 µg/mL) in the BT-Med + BT-TI group compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 70.3% and 106% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively 1 µg/mL compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 95.9% in the UT-Med + BT-TI group at 0.1 µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 58.4% and 135.9% in the BT-Med + BT-TI group at 10 and 25 µg/mL, respectively; while 72.8% (at 25 µg/mL) in the BT-Med + UT-TI group as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 373.2% (at 1 µg/mL) and 263.1% (at 10 µg/mL) in the BT-Med + UT-TI group; while 318.4% (at 1 µg/mL) and 224.4% (at 10 µg/mL) in the BT-Med + BT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, hemochromatosis, cirrhosis, liver cancer, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[5] viXra:1909.0054 [pdf] submitted on 2019-09-04 04:24:22

Analysis of the Biofield Energy Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Based Assay

Authors: Maria Isabel Aguilar Tiraboschi, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 11 Pages.

Vital organs dysfunction is one of the major concerns now-a-day, which results in high mortality rate in health care centers. Thus, growth and normal functioning of the vital organs is the major concern for better health. The aim of this study was to investigate the impact of the Biofield Energy on the test formulation and the cell line media for the function of vital organs such as bones, heart, liver, lungs, and brain using cell-based assays. Different organ-based cell lines were used in the study for testing the effects of test formulation. The test item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Maria Isabel Aguilar Tiraboschi, Uruguay and were labeled as the Biofield Energy Treated (BT) test formulation. Cell viability data suggested that the test formulation was safe and non-toxic in nature in the tested cell lines. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 23.7% (at 25.5µg/mL), 54.1% (at 10µg/mL), and 81.6% (at 63.75µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 53.4% (at 63.75µg/mL), 20.2% (at 63.75µg/mL), and 43.9% (at 10µg/mL) improved cellular protection of human hepatoma cells (HepG2) cells in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 121.9% (at 1µg/mL), 416% (at 25.5µg/mL), and 323% (at 25.5µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 78.2% at 50µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 67.5% at 50µg/mL in the BT-Med + UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 26.6% (at 25.5µg/mL), 37.9% (at 10µg/mL), and 76.5% (at 25.5µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 21.1% (at 10µg/mL), 93.9% (at 63.75µg/mL), and 51.4% (at 63.75µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 57.2% (at 25.5µg/mL), 176.9% (at 10µg/mL), and 184.2% (at 10µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 34.8% (at 63.75µg/mL), 65.4% (at 63.75µg/mL), and 398.7% (at 1µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med+BT-TI groups, respectively compared to the untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 207.9% (at 0.1µg/mL), 37.1% (at 10µg/mL), and 141% (at 10µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[4] viXra:1909.0053 [pdf] submitted on 2019-09-04 04:25:02

Biological Significance of the Biofield Energy Treatment Based Test Formulation on Various Biomarkers Using Cell-Based Assays

Authors: Dimitrius Anagnos, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Comments: 10 Pages.

The aim of the present study determined the impact of the Biofield Energy Treated test formulation using cell lines related with vital organs functioning. Different cells based assay were used based on the vital organs function of bones, heart, liver, lungs, and brain. The test formulation and cells media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Dimitrius Anagnos, USA and were labeled as the Biofield Energy Treated (BT) test formulation / media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found non-toxic against all the cell line. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 25.6% (at 63.75 µg/mL), 46.7% (at 0.1 µg/mL), and 109.5% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 41.3%, 22.8%, and 34.8% at 63.75 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. However, cyto-protective activity in human hepatoma cells (HepG2) showed improved cell viability by 117.7% (at 0.1 µg/mL), 61.3% (at 25.5 µg/mL), and 104% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was significantly increased by 105.7% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 368% and 602% at 0.1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups respectively, as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 58.8% at 1 µg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 32.6% at 25 µg/mL, and improved cellular protection by 60.4% and 109.5% at 25 and 63.75 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 35.9% (at 10 µg/mL), 84.2% (at 25.5 µg/mL), and 87.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 35.2% (at 0.1 µg/mL), 35.2% (at 0.1 µg/mL), and 79.7% (at 1 µg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased at 25 µg/mL by 30.6%, 107.7%, and 89.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased at 50 µg/mL by 156.1%, 158.7%, and 68.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
Category: Biochemistry

[3] viXra:1909.0052 [pdf] submitted on 2019-09-04 04:25:27

Antioxidant and Organ Protective Potential of the Consciousness Energy Healing-Based Novel Test Formulation Using Different Biomarkers Analysis

Authors: Kathryn Regina Sweas, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 12 Pages.

The aim of this paper was to investigate the impact of the Biofield Energy Treatment on the test formulation by focusing on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Kathryn Regina Sweas, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The experimental group of Biofield Treated medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 53.5%, 127.9%, and 53.3% restoration of cell viability, at 0.1, 10, and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, UT-Med + BT-TI and BT-Med + BT-TI groups showed 42.4% (at 25 µg/mL) and 72.6% (at 0.1 µg/mL), restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 67.7% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 80.7%, 85%, and 93.7% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 65.8% (at 25 µg/mL) and 106.7% (at 50 µg/mL) in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 100.9% (at 0.1 µg/mL) and 91.2% (at 10 µg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 51.5% and 133.6% at 10 and 63 µg/mL, respectively in the BT-Med + BT-TI group compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 55.8% (at 10 µg/mL) and 43.8% (at 1 µg/mL) in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to the untreated in A549 cells. Serotonin level was significantly increased by 80%, 77.2%, and 58.7% in the BT-Med + BT-TI group at 10, 25, and 63 µg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 136.8%, 191.9%, and 165.8% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL compared to the untreated in MG-63 cells. Altogether, results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers also to protect and maintain the normal function of each vital organs. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, congenital heart disease, heart failure, arrhythmias, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, chronic bronchitis, asthma, cystic fibrosis, emphysema, osteoporosis, etc.
Category: Biochemistry

[2] viXra:1909.0031 [pdf] submitted on 2019-09-03 04:21:55

The Impact of the Consciousness Energy Healing Treated Test Formulation on Vital Organs Health Biomarkers

Authors: Joy Angevin Balmer, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 14 Pages.

The study was performed to find out the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Joy Angevin Balmer, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Energy Treated medium (BT-Med) + Biofield Treated test item (UT-TI) group showed 149.3% restoration of cell viability at 1 µg/mL as compared to the UT-Med + UT-TI group in human cardiac fibroblasts cells (HCF). Moreover, the UT-Med + BT-TI and BT-Med + BT-TI groups showed 54.2% (at 0.1 µg/mL) and 43.5% (at 63 µg/mL) restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 58.3% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI group at 0.1 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 92.4%, 72.1%, and 87.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 64.7% (at 25 µg/mL) and 87.9% (at 50 µg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 163% and 80.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1 µg/mL compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 89.3% and 60.4% at 1 µg/mL in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 61.1% (at 1 µg/mL) and 43.5% (at 63 µg/mL) in the BT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to untreated in A549 cells. Serotonin level was significantly increased by 32.5% and 34.2% in the BT-Med + BT-TI group at 10 and 63 µg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 174.4% (at 10 µg/mL), 212% (at 1 µg/mL), and 196.1% (at 0.01 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.
Category: Biochemistry

[1] viXra:1909.0030 [pdf] submitted on 2019-09-03 04:22:32

The Potential of the Biofield Energy Treated Novel Proprietary Test Formulation on Organs Specific Biomarkers

Authors: Inthirani Arul, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
Comments: 15 Pages.

The study was investigated to find out the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Inthirani Arul, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Energy Treated medium (BT-Med) + untreated test item (UT-TI) group showed 97.9% and 88.9% restoration of cell viability at 10 and 25 µg/mL, respectively as compared to the UT-Med + UT-TI group in human cardiac fibroblasts cells (HCF). Moreover, BT-Med + BT-TI group showed 62.8% and 86.2% restoration of cell viability at 1 and 63 µg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 125.6% (at 0.1 µg/mL) and 94.8% (at 63 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 81.8%, 83.9%, and 83.2% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 1430% (at 0.1 µg/mL), 332.6% (at 1 µg/mL), and 265% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 69% (at 1 µg/mL), 100.9% (at 0.1 µg/mL), and 76.9% (at 25 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 44.4% (at 0.1 µg/mL), 63.9% (at 10 µg/mL), and 84.9% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 35.1% and 78.3% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 71.6%, 82.8%, and 104.8% in the BT-Med + BT-TI group at 1, 10, and 25 µg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 253.5% (at 1 µg/mL) and 270.3% (at 50 µg/mL) in the BT-Med + BT-TI group; while 235.2% at 10 µg/mL in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver, lungs, and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.
Category: Biochemistry